Processa Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Processa Pharmaceuticals hat ein Gesamteigenkapital von $2.5M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $4.5M bzw. $2.0M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$1.69m
Eigenkapital	US$2.54m
Gesamtverbindlichkeiten	US$1.98m
Gesamtvermögen	US$4.52m

Jüngste Berichte zur Finanzlage

Analyseartikel • Dec 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Oct 20

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • Jul 07

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Recent updates

Analyseartikel • Dec 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Oct 20

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 12

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Processa Pharmaceuticals press release (NASDAQ:PCSA): Q2 GAAP EPS of $0.53 beats by $0.73. Company cash balance on June 30, 2022, was $12.1 million,

Analyseartikel • Jul 07

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyseartikel • Jan 20

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Aug 26

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analyseartikel • Mar 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

The big shareholder groups in Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) have power over the company. Institutions...

Analyseartikel • Jan 20

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PCSADie kurzfristigen Aktiva des Unternehmens ($1.9M) decken seine kurzfristigen Passiva ($2.0M) nicht.

Langfristige Verbindlichkeiten: PCSA hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PCSA ist schuldenfrei.

Schulden abbauen: PCSA hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 0.5% betrug.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: PCSA hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: PCSA hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 17.9% pro Jahr abnimmt

Entdecken Sie finanziell stabile Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/20 13:17
Aktienkurs zum Tagesende	2026/05/20 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Processa Pharmaceuticals, Inc. wird von 4 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Robin Garner Kalley	Craig-Hallum Capital Group LLC
Raghuram Selvaraju	H.C. Wainwright & Co.
Nazibur Rahman	Maxim Group

Processa Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Processa Pharmaceuticals Receives Notice from Nasdaq Regarding the Bid Price Requirement Compliance

Processa Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Bid Price Requirement

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Recent updates

Processa Pharmaceuticals, Inc. Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Processa Pharmaceuticals, Inc. Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

New major risk - Market cap size

New minor risk - Profitability

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 Pcs499 Study in Fsgs At Asn Kidney Week 2025

Processa Pharmaceuticals Receives Notice from Nasdaq Regarding the Bid Price Requirement Compliance

Processa Pharmaceuticals, Inc. announced that it has received $1.257452 million in funding

Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline

New major risk - Share price stability

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

New major risk - Financial position

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 30, 2025

Processa Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Bid Price Requirement

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.999298 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. Announces Positive Preclinical Data for NGC-IRI

New major risk - Financial position

Processa Pharmaceuticals, Inc. Announces FDA Clearance of IND Application for A Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals, Inc. Announces CFO Changes

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial

New major risk - Shareholder dilution

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

New major risk - Share price stability

New major risk - Market cap size

Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals, Inc. Provides Update on Enrollment Across All Clinical Programs

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Board Changes

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc., Annual General Meeting, Jul 11, 2022

Price target decreased to US$15.00

Processa Pharmaceuticals, Inc. Doses First Patient in Amended Phase 1B Protocol for Pcs6422 Combined with Capecitabine

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Co-Founder recently bought US$77k worth of stock

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals, Inc. announced that it has received $10.238773 million in funding

New 90-day high: US$10.89

Processa Pharmaceuticals, Inc. announced that it expects to receive $10.238773 million in funding

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Processa Pharmaceuticals, Inc. Announces Executive Changes

Processa Pharmaceuticals, Inc. Appoints R. Michael Floyd as Chief Operating Officer

Co-Founder recently bought US$125k worth of stock